Roland Griffiths was the founding Director of the Johns Hopkins Center for Psychedelic and Consciousness Research and one of the most cited researchers in the field of psychedelic medicine. His landmark 2006 Nature paper — widely considered the foundational study of the modern psychedelic renaissance — established that psilocybin reliably occasions mystical experiences rated among the most personally meaningful events of participants' lives. His subsequent work on terminal cancer patients (2016, Journal of Psychopharmacology) showed 80% long-term reduction in anxiety and depression after a single session. He co-developed the MEQ30 scale — the standard validated instrument for measuring mystical experience in clinical research.
Griffiths spent the first 25 years of his career studying the behavioral pharmacology of caffeine and benzodiazepines — establishing foundational work on drug reinforcement and physical dependence before pivoting to psilocybin research in the late 1990s. The pivot was motivated partly by personal curiosity and partly by a conviction that consciousness research was the most important neglected frontier in neuroscience. He spent years navigating DEA and FDA regulatory frameworks before the first participants entered his historic 2006 study.
His 2006 paper in Psychopharmacology — "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance" — is one of the most cited in psychedelic science history. The rigorous double-blind, placebo-controlled design, the 14-month follow-up assessments, and the frank engagement with subjective experience convinced a skeptical scientific community that these phenomena were worth studying seriously. A 2011 follow-up found that 83% of participants still rated their session as among the five most personally meaningful experiences of their lives.
Griffiths co-founded the Center for Psychedelic and Consciousness Research at Johns Hopkins in 2019 — the first such center at a major U.S. research university. Until his death from cancer in October 2023, he remained actively involved in research on psilocybin for cancer distress, major depression, and tobacco addiction. His legacy is the modern clinical trial framework for psychedelic medicine, and the proof-of-concept evidence that changed regulatory, academic, and public understanding of these compounds.